Meta-analysis of Shenqi Fuzheng Injection Combined with Chemotherapy for Colorectal Cancer / 中国药房
China Pharmacy
;
(12): 248-254, 2018.
Artigo
em Chinês
| WPRIM
| ID: wpr-704562
ABSTRACT
OBJECTIVE:
To evaluate the clinical efficacy and safety of Shenqi fuzheng injection combined with chemotherapy in the treatment of colorectal cancer.METHODS:
Retrieved from PubMed,EMBase,Clinical Trials,Cochrane Library,CJFD,CBM,Wanfang database and VIP,RCTs about Shenqi fuzheng injection combined with chemotherapy (trial group) vs.chemotherapy alone (control group) in the treatment of colorectal cancer were included.Meta-analysis was performed by Rev Man 5.3 statistical software after data extraction and quality evaluation with Cochrane system evaluator manual.RESULTS:
A total of 25 RCTs were included,involving 1 987 patients.Results of Meta-analysis showed that objective remission rate of trial group was significantly higher than control group [RR=1.19,95% CI (1.02,1.39),P=0.02];the improvement of survival quality was significantly better than control group [RR=1.72,95%CI(1.49,1.99),P<0.001];CD4VCD8+ was significantly higher than control group [MD=0.40,95% CI (0.29,0.50),P<0.001];the incidence of gastrointestinal reaction was significantly higher than control group [RR=0.59,95%CI(0.52,0.68),P<0.001];the incidence of liver and renal injury was significantly lower than control group [RR=0.52,95%CI(0.41,0.67),P<0.001],with statistical significance.CONCLUSIONS:
Shenqi fuzheng injection combined with chemotherapy can improve objective remission rate of colorectal cancer patients,survival quality and immune function,and reduce the occurrence of toxic reation.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Tipo de estudo:
Guia de Prática Clínica
/
Revisões Sistemáticas Avaliadas
Idioma:
Chinês
Revista:
China Pharmacy
Ano de publicação:
2018
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS